Pfizer Options Spot-On: On May 1st, 114.11K Contracts Were Traded, With 3.5 Million Open Interest
Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges
The Pfizer Inc. (NYSE:PFE) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $26
Express News | Arvinas Inc: Co, Pfizer, Inc., Removed Two Planned Phase 3 Combination Trials of Vepdegestrant From the Agreed-Upon Joint Development Plan
Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com
FDA to Tighten Vaccine Approval Requirements: Reports
Trump Administration Said to Be Investing $500M on Developing Universal Vaccines
Zacks.com Featured Highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander
Hold Rating on Pfizer Amid Political Challenges in Biopharmaceutical Sector
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
Eli Lilly's Earnings Report Will Bring a Focus on Tariffs, Not Profits
Pfizer Options Spot-On: On April 30th, 219.31K Contracts Were Traded, With 3.42 Million Open Interest
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion
SA Analyst Upgrades: PFE, ALLY, TMUS, ECC, CRK
Pfizer Analyst Ratings
BofA Securities Adjusts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating
UBS Adjusts Price Target on Pfizer to $25 From $24, Maintains Neutral Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $24 to $32
Daily short sale tracking: Amcor's short volume increased by 49 million, with a short sale ratio of 39%